Related Experiment Videos
Emerging drugs for acute and chronic heart failure: current and future developments
Stephen Y Chen1, W H Wilson Tang
1Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Expert Opinion on Emerging Drugs
|March 16, 2007
Summary
Novel heart failure treatments are being investigated to improve patient outcomes. These new therapies target congestion, renal function, stiffness, contractility, and metabolic balance for better heart health.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Heart failure remains a significant public health concern with high morbidity and mortality despite current therapies.
- Existing treatments like angiotensin-converting enzyme inhibitors and beta-adrenergic blockers have limitations.
- Current therapeutic options for acute decompensated heart failure and heart failure with preserved ejection fraction are insufficient.
Purpose of the Study:
- To provide an overview of novel compounds and strategies under investigation for heart failure treatment.
- To highlight emerging therapeutic approaches beyond established treatments.
Main Methods:
- This is a review article, synthesizing information on new drug candidates and therapeutic strategies.
- The review covers various classes of novel compounds targeting different pathophysiological aspects of heart failure.
Main Results:
- Novel drug strategies aim to alleviate congestion and improve hemodynamics.
- Emerging treatments focus on preserving renal function and reducing arterial and myocardial stiffness.
- Investigational drugs also modulate myocardial contractility, affect metabolic and hormonal balance, and target novel physiological pathways.
Conclusions:
- Significant research is underway to develop improved treatments for heart failure.
- These novel strategies offer potential for better management of heart failure, addressing unmet clinical needs.
- Future therapies may provide more effective options for diverse heart failure phenotypes.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.